RxDoctor Payments Data

Lori Wink

Women's Health · Houston, TXNPI 1295279750

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (48.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Sumitomo Pharma America, Inc. at 35.8% of the total. Reporting peaked in 2023 at $6,348 and has fallen 90.1% since, to $627 in 2025. Among women's health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,820in general payments, 2019–2025

Across 134 payments — averaging $65.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$3K
  • Pfizer$3K
  • Myovant Sciences Inc.$497
  • Astellas Pharma Global Development$333
  • Mayne Pharma Commercial LLC$185
  • Bayer$179
  • plus $1K from 23 others

What the payments were for

  • Speaking & faculty fees$4,29649%
  • Travel & lodging$1,08512%
  • Food & beverage$3,42139%
  • Gifts$180%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,820 in reported general payments places this provider in the 95th percentile of 609 women's health providers in Texas.

See all women's health providers in Texas

Medicare billing

Part B allowed, 2024
$1,169
Medicare patients
16
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol19$1,595
Metronidazole12$256

Paid to pharmacies, not to this prescriber.

Other women's health in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →